News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,862 Results
Type
Article (20073)
Company Profile (128)
Press Release (313661)
Multimedia
Podcasts (72)
Webinars (11)
Section
Business (105430)
Career Advice (879)
Deals (18535)
Drug Delivery (97)
Drug Development (50797)
Employer Resources (79)
FDA (7703)
Job Trends (7750)
News (185970)
Policy (17357)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (736)
Accelerated approval (3)
Adcomms (17)
Allergies (41)
Alliances (27863)
ALS (54)
Alzheimer's disease (640)
Antibody-drug conjugate (ADC) (93)
Approvals (7713)
Artificial intelligence (141)
Autoimmune disease (16)
Automation (6)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (98)
Biotechnology (57)
Bladder cancer (33)
Brain cancer (19)
Breast cancer (111)
Cancer (1069)
Cardiovascular disease (115)
Career advice (713)
Career pathing (21)
CAR-T (55)
Cell therapy (153)
Cervical cancer (5)
Clinical research (42719)
Collaboration (476)
Compensation (176)
Complete response letters (23)
COVID-19 (1099)
CRISPR (22)
C-suite (151)
Cystic fibrosis (58)
Data (1137)
Decentralized trials (2)
Denatured (18)
Depression (25)
Diabetes (142)
Diagnostics (1811)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (82)
Drug pricing (110)
Drug shortages (30)
Duchenne muscular dystrophy (60)
Earnings (39082)
Editorial (32)
Employer branding (10)
Employer resources (73)
Events (48669)
Executive appointments (456)
FDA (8300)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (320)
Gene editing (47)
Generative AI (18)
Gene therapy (145)
GLP-1 (600)
Government (1856)
Grass and pollen (3)
Guidances (19)
Healthcare (5904)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (86)
Indications (19)
Infectious disease (1180)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (56)
Interviews (116)
IPO (7371)
IRA (45)
Job creations (2433)
Job search strategy (648)
Kidney cancer (7)
Labor market (24)
Layoffs (279)
Leadership (14)
Legal (4121)
Liver cancer (31)
Lung cancer (163)
Lymphoma (88)
Machine learning (2)
Management (30)
Manufacturing (213)
MASH (50)
Medical device (1964)
Medtech (1967)
Mergers & acquisitions (11428)
Metabolic disorders (503)
Multiple sclerosis (49)
NASH (20)
Neurodegenerative disease (49)
Neuropsychiatric disorders (23)
Neuroscience (959)
NextGen: Class of 2025 (2359)
Non-profit (907)
Northern California (1087)
Now hiring (22)
Obesity (317)
Opinion (190)
Ovarian cancer (33)
Pain (67)
Pancreatic cancer (37)
Parkinson's disease (87)
Partnered (11)
Patents (144)
Patient recruitment (47)
Peanut (16)
People (33503)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13376)
Phase II (18073)
Phase III (14514)
Pipeline (728)
Policy (124)
Postmarket research (1618)
Preclinical (4666)
Press Release (29)
Prostate cancer (61)
Psychedelics (16)
Radiopharmaceuticals (161)
Rare diseases (245)
Real estate (3175)
Recruiting (29)
Regulatory (12553)
Reports (22)
Research institute (819)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (60)
Series A (58)
Series B (34)
Service/supplier (7)
Sickle cell disease (36)
Southern California (1041)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2011)
State (2)
Stomach cancer (9)
Supply chain (55)
Tariffs (35)
The Weekly (52)
United States (10259)
Vaccines (273)
Venture capitalists (29)
Weight loss (243)
Women's health (14)
Worklife (7)
Date
Today (72)
Last 7 days (292)
Last 30 days (1271)
Last 365 days (16722)
2025 (5104)
2024 (17671)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15588)
2017 (17255)
2016 (16202)
2015 (18803)
2014 (14787)
2013 (12553)
2012 (13484)
2011 (13817)
2010 (12740)
Location
Africa (409)
Alabama (23)
Alaska (1)
Arizona (65)
Arkansas (8)
Asia (24917)
Australia (3224)
California (2552)
Canada (1115)
China (328)
Colorado (100)
Connecticut (100)
Delaware (72)
Europe (51468)
Florida (446)
Georgia (55)
Idaho (16)
Illinois (250)
India (20)
Indiana (175)
Iowa (3)
Japan (122)
Kansas (62)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (371)
Massachusetts (2159)
Michigan (48)
Minnesota (139)
Mississippi (1)
Missouri (28)
Montana (10)
Nebraska (11)
Nevada (17)
New Hampshire (8)
New Jersey (1039)
New Mexico (21)
New York (753)
North Carolina (506)
North Dakota (2)
Northern California (1087)
Ohio (83)
Oklahoma (5)
Oregon (21)
Pennsylvania (614)
Puerto Rico (11)
Rhode Island (18)
South America (608)
South Carolina (3)
Southern California (1041)
Tennessee (38)
Texas (339)
Utah (55)
Virginia (85)
Washington D.C. (45)
Washington State (221)
Wisconsin (21)
333,862 Results for "mapi pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
FDA Rejects Viatris, Mapi’s Long-Acting Multiple Sclerosis Injection
With Monday’s FDA rejection of their long-acting glatiramer acetate formulation, Viatris and Mapi Pharma continue the biopharma industry’s recent losing streak in multiple sclerosis.
March 11, 2024
·
2 min read
·
Tristan Manalac
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
April 16, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
·
2 min read
·
Tristan Manalac
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Tariffs
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All
Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.
April 10, 2025
·
2 min read
·
Annalee Armstrong
Policy
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
Viatris Inc., a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review the companies’ recently submitted New Drug Application for GA Depot 40 mg.
August 7, 2023
·
8 min read
Clinical research
Pharma R&D Returns Grow Again, But Deloitte Warns Progress is ‘Fragile’
Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.
March 27, 2025
·
3 min read
·
Annalee Armstrong
Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlight Latest Results on GA Depot in Relapsing MS at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023
Mapi Pharma Ltd. announced that recent clinical data from studies of GA Depot 40 mg will be presented at the forthcoming European Committee for Treatment and Research in Multiple Sclerosis & Americas Committee for Treatment and Research in Multiple Sclerosis meeting to take place in Milan, Italy, October 11 to 13.
October 10, 2023
·
4 min read
1 of 33,387
Next
